Navigation Links
VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
Date:10/29/2009

SAN FRANCISCO, Oct. 29 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.

    The presentation details are as follows:
             Date / Time:   Tuesday November 3, 2009
                            4:20 pm ET
             Location:      InterContinental Hotel, Boston, MA
             Track:         Targeting Diabetes with Novel Therapeutics -
                             Strategically Advancing Clinical Compounds
             Title:         Liver Directed Beta Agonist for Targeting Cardio-
                             metabolic Disease

In addition, Dr. Taub will participate in other forums on Wednesday November 4, 2009, including a panel on the "Clinical Landscape for New Diabetes Drug Candidates".

About THR beta agonist

VIA-3196 is an orally administered, small-molecule beta-selective thyroid hormone receptor agonist designed to specifically target receptors in the liver involved in metabolism and cholesterol regulation, and avoid side effects associated with thyroid hormone receptor activation outside the liver. Roche has completed preclinical studies of the THR beta agonist. These studies demonstrated a rapid reduction of non-HDL cholesterol and the drug was shown to be synergistic with statin
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
2. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
3. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
4. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
5. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
6. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
7. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
9. Onyx Pharmaceuticals to Host Investor Briefing Following ECCO/ESMO Oncology Congress
10. Biostar Pharmaceuticals, Inc. to Present at the Maxim Group Growth Conference on September 29 at 2:00pm ET
11. DUSA Pharmaceuticals to Present at the Maxim Group 3rd Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The Alaska Center for Dentistry at ... Jonathan Oudin, DDS, who will begin working July 21. ... for three years. According to Teresa Wallace, Office Manager, ... help take on new patients. , "This will allow ... serving the greater Anchorage metro community," Wallace said. "Dr. ...
(Date:7/31/2014)... 31, 2014 (HealthDay News) -- Transplant surgeons often ... flags for burnout, a new study suggests. ... study reported having a low sense of personal ... feeling emotionally exhausted, researchers found. "Burnout is ... transplantation," study co-author Dr. Marwan Abouljoud, director of ...
(Date:7/31/2014)... algorithm aimed to diagnose pediatric patients with suspected ... scans, without affecting diagnostic accuracy, Mayo Clinic Children,s ... published in the journal Surgery . , ... acute abdominal pain in children. Appendicitis occurs when ... CT scans are often used to diagnose acute ...
(Date:7/31/2014)... recent fears of invasive lionfish causing fish poisoning may ... by fishing derbies and targeted fisheries may remain the ... simple way to know for sure whether a lionfish ... , Pacific lionfish were first reported off the coast ... swiftly in number ever since. They,re now found in ...
(Date:7/31/2014)... July 31, 2014 Setting goals for a ... blogs on successful tips to weight loss. Fitness on the ... over 8 years, and has worked with 6000 customers on ... have had the chance to monitor why customers start exercising ... how long they stick to their program, whether or not ...
Breaking Medicine News(10 mins):Health News:Dr. Jonathan Oudin to Join Alaska Center for Dentistry at Wasilla Location 2Health News:Burnout Common Among Transplant Surgeons, Study Reveals 2Health News:Invasive lionfish likely safe to eat after all 2Health News:Invasive lionfish likely safe to eat after all 3Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2
... web for robots this is the aim of a ... Universitaet Muenchen (TUM). This worldwide database will enable robots in ... thus speeding up the process of adopting new operations. The ... and has a budget of 5.6 million euros. One ...
... of Southampton and Synairgen Research Ltd, a respiratory drug ... a Phase II study into the effectiveness of the ... increase in the frequency of asthma attacks (also known ... viruses because the lungs of patients with the condition ...
... ... subliminal and binaural visualization techniques, today announced that his iPhone and iPod touch app ... ... neuropsychologist and expert in subliminal and binaural visualization techniques, today announced that his iPhone ...
... ... Trade World, Inc. group of products. This new agreement covers all of the West ... ... VisionQwest Resource Group, Inc. www.vqrginc.com ) has signed a formal marketing and distribution agreement ...
... ... of Austin Texas announces general availability of the Test Coverage Tool for C# ... new code can be compiled and run to determine exactly what lines of ... graphic display of code coverage along with overall metrics is the result of ...
... ... Behind Their Products , ... UT (Vocus) April 8, 2010 -- Tahitian Noni International (TNI) now has 14 ... on the way. TNI has more human clinical studies than any network marketing superfruit company ...
Cached Medicine News:Health News:European collaboration seeks to create 'World Wide Web' for robots 2Health News:Southampton scientists begin Phase II patient trial for new asthma treatment 2Health News:Sales are on the Rise for Professor McMurphy's Subliminal and Binaural Visualization iPhone Apps 2Health News:Sales are on the Rise for Professor McMurphy's Subliminal and Binaural Visualization iPhone Apps 3Health News:VisionQwest Global Group Signs Distribution Agreement with Creative Trade World, Inc. 2Health News:VisionQwest Global Group Signs Distribution Agreement with Creative Trade World, Inc. 3Health News:Know What Works with Semantic Design's Test Coverage Analysis Tool for C#/.Net 2Health News:Know What Works with Semantic Design's Test Coverage Analysis Tool for C#/.Net 3Health News:14 Human Clinical Studies Prove the Efficacy of Tahitian Noni Bioactive Beverages 2
(Date:7/31/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today ... 2014 of $20.0 million, a 10% increase over $18.2 ... a constant currency basis, revenues grew 11% during the ... of 2013.  The effect of foreign currency exchange reduced ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014  ResMed Inc. (NYSE: ... and for the fiscal year ended June 30, 2014.  Revenue ... quarter ended June 30, 2013 (a 1 percent decrease on ... increase of 20 percent compared to the quarter ended June ... $0.61, an increase of 22 percent compared to the quarter ...
(Date:7/31/2014)... -- Xencor Inc. (NASDAQ: XNCR ), ... for the treatment of autoimmune diseases, asthma and ... for the second quarter ended June 30, 2014 and ... "In the second quarter, we presented preclinical ... Conference (ATS) demonstrating three novel mechanisms of action ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6
Blunt, 20 cm long....
Autoclavable reusable pencil for Aaron 800 & 1200 - comes with generator or 1/box....
400 Series Monopolar Foot Activated Forceps...
Extended angled sharp electrode - 1/box....
Medicine Products: